An­nex­on pro­claims Phase 3 win for com­ple­ment in­hibitor in Guil­lain-Bar­ré Syn­drome

An­nex­on Bio­sciences re­port­ed new Phase 3 da­ta for its Guil­lain-Bar­ré Syn­drome (GBS) drug Tues­day morn­ing, say­ing the low dose achieved the tri­al’s pri­ma­ry end­point. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER